Case Details
- Citation: [2011] SGHC 71
- Title: Martek Biosciences Corporation v Cargill International Trading Pte Ltd
- Court: High Court of the Republic of Singapore
- Date of Decision: 29 March 2011
- Case Number: Originating Summons No. 156 of 2010
- Coram: Tay Yong Kwang J
- Tribunal/Decision Under Appeal: Deputy Registrar of Patents and Principal Assistant Registrar of Patents (IPOS Tribunal)
- Date of Tribunal Decision: 31 December 2009
- Applicant/Proprietor: Martek Biosciences Corporation
- Respondent: Cargill International Trading Pte Ltd
- Procedural Posture: Appeal by Applicant; Respondent also appealed/cross-appealed on aspects of amendment objections
- Key Proceedings Below: Revocation Proceedings and Amendment Proceedings (consolidated and heard together)
- Legal Area: Patents and Inventions
- Statutes Referenced: Patents Act (Cap 221, 2005 Rev Ed) (“Act”)
- Cases Cited: [2011] SGHC 71 (as provided in metadata/extract)
- Judgment Length: 19 pages, 10,337 words
- Counsel for Applicant: Dr Stanley Lai, SC and Mr Vignesh Vaerhn (Allen & Gledhill LLP)
- Counsel for Respondent: Mr Daniel Koh (instructed) (Eldan Law LLP) and Ms Wendy Low Wei Ling (Rajah & Tann LLP)
- Patent at Issue: Singapore Patent P-No. 49307, entitled “Microbial Oil Mixtures and Use Thereof”
- Patent Grant Date: 10 January 2002
- Application Date: 13 April 1996 (under s 116(6) of the Patents Act (Cap 221, 1995 Rev Ed))
- Amendment Sets: 1997 Amendments (2 July 1997); 1999 Amendments (13 October 1999); Proposed 2006 Amendments (filed with leave; advertised 30 October 2006); Proposed 2008 Amendments (filed 19 March 2008; advertised 28 May 2008)
Summary
Martek Biosciences Corporation v Cargill International Trading Pte Ltd concerned an appeal to the High Court against an IPOS Tribunal decision that had revoked Martek’s Singapore patent relating to “Microbial Oil Mixtures and Use Thereof”. The patent proprietor, Martek, had faced revocation proceedings brought by Cargill on multiple statutory grounds, including lack of patentable subject matter, insufficiency, and alleged “added matter” arising from amendments. In parallel, Cargill objected to various sets of proposed amendments that Martek sought to introduce into the patent during the course of the proceedings.
The High Court (Tay Yong Kwang J) allowed Martek’s appeal against the Tribunal’s decision in the revocation proceedings. In substance, the Court held that the patent, as amended by the 1999 Amendments (subject to an exception relating to claim 30), was valid. The Court also dismissed both parties’ appeals and cross-appeals concerning the Tribunal’s handling of the amendment proceedings, save for a specific issue relating to Claim 42 and consequential Claim 45 in the Proposed 2006 Amendments.
Beyond the immediate outcome, the decision is notable for its approach to structuring the analysis: the judge preferred to assess validity first (as amended) before turning to whether particular amendment sets were allowable. The judgment also illustrates the evidential scrutiny applied to expert testimony in patent disputes, particularly where experts’ expertise may not align precisely with the technical field in question or where hindsight concerns arise.
What Were the Facts of This Case?
Martek Biosciences Corporation is a Delaware-incorporated company and the proprietor of Singapore Patent P-No. 49307, entitled “Microbial Oil Mixtures and Use Thereof”. The patent was granted by IPOS on 10 January 2002 following an application filed on 13 April 1996. The invention, as described in the abstract, relates to compositions that blend microbial oils, methods of using such compositions—particularly as supplements for infant formula—and methods of increasing long chain polyunsaturated fatty acids (“lcPUFAs”) in infant formula.
The technical subject matter is grounded in the chemistry of fatty acids. The judgment explains that polyunsaturated fatty acids (“PUFAs”) are fatty acids with at least two carbon double bonds in their fatty acid tail, while lcPUFAs are PUFAs with at least 20 carbon atoms in the tail. The patent’s relevance to infant nutrition is tied to the presence of specific lcPUFAs such as arachidonic acid (“ARA”) and docosahexaenoic acid (“DHA”), which belong to omega-6 and omega-3 families respectively.
Procedurally, the patent’s prosecution and subsequent litigation involved multiple amendment stages. Prior to grant, Martek filed two sets of amendments: the 1997 Amendments (dated 2 July 1997) and the 1999 Amendments (dated 13 October 1999). After grant, Cargill initiated revocation proceedings on 20 January 2006. Cargill’s revocation application relied on three principal grounds under the Patents Act: (1) that the invention was not a patentable invention under s 80(1)(a); (2) insufficiency under s 80(1)(c), alleging that the specification did not disclose the invention clearly and completely for it to be performed by a person skilled in the art; and (3) that the 1999 Amendments added matter beyond what was disclosed in the application as filed, contrary to s 80(1)(d)(i).
During the revocation and opposition landscape, Martek also sought to amend the patent further. It filed Proposed 2006 Amendments pursuant to s 83 and the Patents Rules, and these were advertised in The Patents Journal on 30 October 2006. Cargill opposed those amendments during the allowable opposition period, alleging that the Proposed 2006 Amendments extended beyond the original application and were therefore not allowable under s 84(3)(a). Martek later obtained leave to file Proposed 2008 Amendments (filed 19 March 2008), which were advertised on 28 May 2008. Cargill objected by letter dated 27 March 2008, alleging that the amendments extended the protection conferred by the patent. At a case management conference, IPOS indicated an intention to re-examine the patent under s 80(2), and a re-examination report was produced by an examiner from the Danish Patent and Trademark Office.
What Were the Key Legal Issues?
The High Court had to determine whether the Tribunal was correct in revoking the patent. This required the Court to consider the statutory grounds invoked by Cargill, particularly whether the invention was patentable, whether the specification was sufficient, and whether the 1999 Amendments introduced added matter beyond the original disclosure. The Court’s task was not merely to review the Tribunal’s conclusions in the abstract, but to assess the validity of the patent as amended by the relevant amendment set—at least as far as the grounds and claims in issue required.
In addition, the Court had to address the amendment proceedings. The Tribunal had ruled on the allowability of the Proposed 2006 and Proposed 2008 Amendments, including whether they met the requirements of s 84 and whether the claims were patentable. The parties’ appeals and cross-appeals meant the High Court needed to consider whether the Tribunal’s approach to amendment allowability and patentability was correct, and whether any particular claims should be treated differently.
Finally, the evidential issues formed part of the legal analysis. Patent cases often turn on technical construction and the assessment of whether prior art disclosures anticipate or render claims obvious, and whether the specification enables the invention. Here, the Court had to evaluate expert testimony, including concerns about whether an expert’s evidence was confined to reply, whether prejudice arose from procedural decisions, and whether an expert’s conclusions were influenced by hindsight after reading the patent.
How Did the Court Analyse the Issues?
The judge began by setting out the procedural history and the scope of the appeals. The High Court noted that the Tribunal had consolidated the revocation and amendment proceedings and heard them together. The Tribunal’s decision, in summary, had been that the 1999 Amendments were allowable under s 84 except for claim 30; that the Proposed 2006 and 2008 Amendments contained some claims not meeting s 84; that all claims in the Proposed 2006 and 2008 Amendments and the 1999 Amendments were not patentable; and that all claims in those amendment sets met the threshold of sufficiency. The Tribunal had therefore ordered revocation and costs.
Importantly, the High Court adopted a different analytical sequence from the Tribunal. The judge observed that the Tribunal had examined allowability of each amendment set before examining validity of the patent as amended by each set. The judge considered that a better approach would be to first examine whether the patent is valid and, if so, then to examine whether the respective sets of amendments are allowable. Accordingly, the Court proceeded to examine validity first, focusing on the patent as amended by the 1999 Amendments (save for claim 30). The Respondent did not appeal the Tribunal’s decision to allow the 1999 Amendments, except for claim 30, which meant the High Court’s validity analysis was anchored on the claims that remained in play after that concession.
On the evidential front, the Court addressed expert testimony issues that could affect the weight given to technical evidence. The Respondent’s witnesses included Dr Puah and Dr Nga. Dr Puah’s statutory declaration was not cross-examined because the Respondent withdrew him from taking the stand, leaving the Applicant unable to test his evidence. The judge identified this as a significant issue and later dealt with it in the judgment. This highlights a practical litigation point: where statutory declarations are admitted but cross-examination is not available, the court may treat the evidence with caution, particularly if it is central to contested technical conclusions.
As for Dr Nga, the judge noted admissions that he was not an expert in the use of microbial oils in the human diet and lacked broad knowledge of general nutrition and paediatric nutrition. Further, during cross-examination, Dr Nga admitted that his evidence and conclusions on prior art documents were made with the benefit of hindsight after reading the patent. The Tribunal had therefore held it would be “cautious” about relying on Dr Nga’s evidence. The High Court treated these concerns as relevant to how much weight should be given to the expert’s interpretation of prior art and the technical framing of the case.
On the Applicant’s side, the Court considered the testimony of Dr Lien and Dr Kyle. Dr Lien was a consultant to the Applicant and an expert in dietary fatty acids and proteins and infant formula research. The Respondent had questioned his objectivity below but did not challenge his testimony during cross-examination, leaving his evidence unchallenged. Dr Kyle was the sole inventor of the patent and an expert in micro-organisms and PUFAs found in polar and non-polar lipids. The Tribunal had accepted their testimonies where relevant but scrutinised them with greater care due to an increased likelihood of bias. The High Court’s analysis reflects a common patent litigation theme: expert evidence is rarely disregarded entirely, but its reliability may be assessed through the lens of expertise, independence, and whether the expert’s reasoning is anchored in the prior art rather than in hindsight.
Although the extract provided does not include the full legal reasoning on each statutory ground, the structure of the judgment indicates that the Court applied the Patents Act’s requirements for patentability, sufficiency, and added matter. The Court’s ultimate decision to allow the appeal against revocation implies that the High Court found at least one of the revocation grounds not made out against the patent as amended by the 1999 Amendments (save for claim 30). The Court also dismissed most aspects of the parties’ amendment-related appeals, indicating that the Tribunal’s approach to allowability and patentability largely stood, except for the specific correction relating to Claim 42 and consequential Claim 45 in the Proposed 2006 Amendments.
What Was the Outcome?
The High Court allowed Martek’s appeal against the Tribunal’s decision in the revocation proceedings. Practically, this meant that Cargill’s attempt to revoke the patent failed (subject to the Tribunal’s and the Court’s treatment of claim 30, and subject to the limited amendment-related correction described below). The Court therefore rejected the revocation outcome that had been ordered by the Tribunal.
As to the amendment proceedings, the High Court dismissed both parties’ appeals and cross-appeals against the Tribunal’s decision relating to the objections to Martek’s various sets of amendments, except with regard to Claim 42 and consequently Claim 45 in the Proposed 2006 Amendments. This indicates that while the patent’s overall validity survived, the Court made a targeted adjustment in relation to the scope and/or allowability of those particular claims.
Why Does This Case Matter?
This decision is significant for patent practitioners in Singapore because it demonstrates how the High Court will structure its review of IPOS Tribunal decisions in complex amendment-and-revocation litigation. The judge’s preference for examining validity first (as amended) before turning to amendment allowability is a useful methodological point. It can reduce analytical duplication and ensure that amendment issues are addressed in a context where the patent’s baseline validity is established.
Substantively, the case underscores the importance of claim-by-claim analysis in revocation proceedings, particularly where only certain claims are challenged or where concessions are made (as with claim 30). The Court’s willingness to allow the patent’s validity while still making a limited correction to specific claims in the Proposed 2006 Amendments reflects a nuanced approach: even where a patent survives, not every amendment or claim formulation will necessarily be accepted.
Finally, the judgment illustrates evidential discipline in patent disputes. The Court’s attention to whether experts were cross-examined, whether their evidence was confined to reply, and whether their conclusions were influenced by hindsight provides practical guidance for litigators. Expert evidence is often decisive in technical patent cases, and this decision shows that courts will scrutinise the independence and methodological soundness of expert reasoning, especially when the expert’s expertise does not perfectly match the claimed invention’s technical domain.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed) (“Act”)
- Section 80(1)(a)
- Section 80(1)(c)
- Section 80(1)(d)(i)
- Section 80(2)
- Section 83
- Section 83(2)
- Section 84(3)(a)
- Section 116(6) (as referenced for the application route under the earlier 1995 Rev Ed version)
- Patents Rules (Cap 221, R1, 1996 Rev Ed)
- Rule 80(3)
- Rule 81(1)(a)
- Rule 85(1)
Cases Cited
- [2011] SGHC 71 (as provided in the supplied metadata/extract)
Source Documents
This article analyses [2011] SGHC 71 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.